Aligos Therapeutics, Inc.

NASDAQ:ALGS

10.18 (USD) • At close September 19, 2024
Bedrijfsnaam Aligos Therapeutics, Inc.
Symbool ALGS
Munteenheid USD
Prijs 10.18
Beurswaarde 62,696,828
Dividendpercentage 0%
52-weken bereik 8.7 - 30
Industrie Biotechnology
Sector Healthcare
CEO Dr. Lawrence M. Blatt MBA, Ph.D.
Website https://www.aligos.com

An error occurred while fetching data.

Over Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184,

Vergelijkbare Aandelen

Reneo Pharmaceuticals, Inc. logo

Reneo Pharmaceuticals, Inc.

RPHM

1.51 USD

Vaccinex, Inc. logo

Vaccinex, Inc.

VCNX

4.55 USD

Sensei Biotherapeutics, Inc. logo

Sensei Biotherapeutics, Inc.

SNSE

0.49 USD

Daxor Corporation logo

Daxor Corporation

DXR

9.15 USD

Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF

2.53 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)